DexCom’s continuous glucose monitor
This article was originally published in The Gray Sheet
Executive Summary
DexCom plans a limited launch of Seven, its next-generation, seven-day STS continuous glucose monitor, at the end of the second quarter followed by a "more robust launch" in the third quarter, the company announces May 31 upon the device's FDA approval. The original STS continuous monitor was approved in March 2006, requiring glucose sensors to be replaced every three days (1"The Gray Sheet" May 22, 2006, p. 17). DexCom says it will hold a conference call "to discuss the approval and product launch plans in more detail at a later date"...
You may also be interested in...
Dexcom Makes Final Preparations On Seven-Day Glucose Monitor Submission
Dexcom plans to submit a PMA supplement for its seven-day STS continuous glucose monitoring system by the end of June
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.